Live Breaking News & Updates on Odette Cancer Centre

Stay updated with breaking news from Odette cancer centre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Diagnosed with cancer, this Hamilton man didn't expect to live past 55. The solar eclipse will mark his 60th

On the day of the total solar eclipse, Prof. Eric Seidlitz of Hamilton's McMaster University will not only be experiencing the celestial event of a lifetime, but also a birthday that he at one time was certain he'd never live to see. ....

Arizona , United-states , Portage-la-prairie , Manitoba , Canada , Toronto , Ontario , Grand-canyon , American , Canadian , Las-vegas , Arden-corter

Lutetium Lu 177 Dotatate Reduced Risk of Death By 72% Compared to Comparator in Patients With Advanced GEP-NETs

Radioligands may be able to deliver radiation to advanced tumor cells anywhere in the body.
....

Canada , United-states , Toronto , Ontario , Simron-singh , Jeff-legos , University-of-toronto , Novartis , Odette-cancer-centre-in-ontario , Susan-leslie-clinic , Neuroendocrine-tumours , Odette-cancer-centre

Novartis' innovative drug shows significant positive outcomes in Phase III trial for patients with gastrointestinal cancers - Pharma News

Novartis' innovative drug shows significant positive outcomes in Phase III trial for patients with gastrointestinal cancers - Pharma News
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Toronto , Ontario , Canada , United-states , Sunnybrook , Alberta , American , Jeff-legos , Simron-singh , University-of-toronto , Odette-cancer-centre , American-society-of-clinical-oncology

Novartis Pharma AG: Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

Novartis Pharma AG: Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland , China , Toronto , Ontario , Canada , Sunnybrook , Alberta , Ivrea , Piemonte , Italy , United-states , Haiyan

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2. ....

United-states , Haiyan , Yunnan , China , Italy , Sasayama , Hyogo , Japan , Canada , Spain , Zhejiang , Zaragoza